Dashboard
Manage Tickers

OPRX


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

gold-rises-over-1-arcos-dorados-shares-fall-after-q1-results
Gold Rises Over 1%; Arcos Dorados Shares F...
05/15/2024 18:33:38

jmp-securities-maintains-market-outperform-on-optimizerx-raises-price-target-to-16
JMP Securities Maintains Market Outperform...
05/15/2024 17:42:04

JMP Securities analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price ...

why-bolt-biotherapeutics-shares-are-trading-lower-by-around-34-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Bolt Biotherapeutics Shares Are Tradin...
05/15/2024 17:38:38

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
05/15/2024 16:31:58

nasdaq-surges-150-points-retail-sales-flat-for-april
Nasdaq Surges 150 Points; Retail Sales Fla...
05/15/2024 16:05:39

expert-ratings-for-optimizerx
Expert Ratings For OptimizeRx
05/15/2024 13:00:52

stifel-maintains-buy-on-optimizerx-maintains-13-price-target
Stifel Maintains Buy on OptimizeRx, Mainta...
05/15/2024 11:51:54

Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and maintains $13 price target.

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
05/14/2024 20:31:13

optimizerx-reiterates-fy24-guidance-with-revenue-to-be-at-least-100m-est-101313m-adjusted-ebitda-of-at-least-11m
OptimizeRx Reiterates FY24 Guidance With R...
05/14/2024 20:29:42

optimizerx-q1-adj-011-beats-013-estimate-sales-1969m-beat-1813m-estimate
OptimizeRx Q1 Adj $(0.11) Beats $(0.13) Es...
05/14/2024 20:12:34

OptimizeRx (NASDAQ:OPRX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.13) by...

optimizerx-corporation-says-1q24-revenue-expected-to-grow-over-40-yoy-and-come-in-between-185m-192m-vs-1703m-estimate-company-says-daap-adoption-and-cross-selling-activities-are-tracking-ahead-of-internal-expectations
OptimizeRx Corporation Says 1Q24 Revenue E...
04/26/2024 11:37:50

For the first quarter, the Company expects revenue to increase over 40% year-over-year and come in between $18.5 million and $1...

jmp-securities-reiterates-market-outperform-on-optimizerx-maintains-15-price-target
JMP Securities Reiterates Market Outperfor...
04/16/2024 15:18:48

JMP Securities analyst Constantine Davides reiterates OptimizeRx (NASDAQ:OPRX) with a Market Outperform and maintains $15 pr...

optimizerx-sees-fy24-revenue-of-100m-vs-10473m-est
OptimizeRx Sees FY24 Revenue Of $100M Vs. ...
04/16/2024 11:08:14

optimizerx-q4-adj-eps-026-inline-sales-2840m-beat-2647m-estimate
OptimizeRx Q4 Adj EPS $0.26, Inline, Sales...
04/16/2024 11:06:03

OptimizeRx (NASDAQ:OPRX) reported quarterly adjusted earnings of $0.26 per share which met the analyst consensus estimate. This...

jmp-securities-initiates-coverage-on-optimizerx-with-market-outperform-rating-announces-price-target-of-15
JMP Securities Initiates Coverage On Optim...
04/04/2024 09:02:53

JMP Securities analyst Constantine Davides initiates coverage on OptimizeRx (NASDAQ:OPRX) with a Market Outperform rating an...

where-optimizerx-stands-with-analysts
Where OptimizeRx Stands With Analysts
04/01/2024 18:00:37

stifel-maintains-buy-on-optimizerx-maintains-13-price-target
Stifel Maintains Buy on OptimizeRx, Mainta...
04/01/2024 15:05:16

Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and maintains $13 price target.

rbc-capital-reiterates-outperform-on-optimizerx-maintains-17-price-target
RBC Capital Reiterates Outperform on Optim...
04/01/2024 13:50:42

RBC Capital analyst Sean Dodge reiterates OptimizeRx (NASDAQ:OPRX) with a Outperform and maintains $17 price target.

earnings-scheduled-for-march-28-2024
Earnings Scheduled For March 28, 2024
03/28/2024 09:24:44

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per ...

optimizerx-earnings-preview
OptimizeRx Earnings Preview
03/27/2024 17:01:50

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)